Science Immunology Under Review: What the Status Means

The first Science Immunology status period is not the full scientific review. It is the AAAS team checking whether this record can be handled: files open correctly, author metadata is complete, disclosures are included, ethics statements are present, and the manuscript appears to match the journal's scope. For Science Immunology, this stage matters because a small administrative issue can look like a peer-review delay from the author's side. If the status changes quickly to Under Review, read that as a routing signal, not as proof that every reviewer has accepted.

The useful Science Immunology action during this stage is not to ask whether the Science Immunology editor likes the paper. It is to make sure every status email, submission-form field, and manuscript file points to the same claim. A mismatch between the cover letter, abstract, figure sequence, methods, data, or supplementary files creates editorial friction even when the work is credible. For Science Immunology, the file package should make clear that the manuscript is ready on AAAS submission files, article type, Science-family cover letter, broad immunology claim, figure sequence, methods completeness, human or animal ethics, data availability, reagent identifiers, statistical analysis, preprint and prior-publication statements, and supplementary-material discipline rather than a generic manuscript looking for a prestigious home before a reviewer has to reconstruct the claim.

At this point the manuscript is being read for fit. The editor is not only asking whether the manuscript is polished, but whether the manuscript makes cross-immunology significance, mechanism versus phenotype, model relevance, translational bridge where claimed, reagent and dataset trust, breadth beyond one subfield, and routing against Nature Immunology, Immunity, JEM, Cell Host and Microbe, or Science Translational Medicine visible quickly enough to justify outside review. A manuscript can be technically careful and still difficult to route if the abstract promises one contribution while the methods, figures, data, or supplementary files support another.

The editor may be matching the manuscript to innate-immunity reviewers, adaptive-immunity reviewers, infection or host-pathogen reviewers, human-immunology reviewers, systems-immunology reviewers, translational reviewers, and editors who can judge whether the claim belongs in a Science-family immunology journal. That matching process can take time because the editor needs reviewers who can evaluate the central claim without rebuilding the manuscript's logic from scratch. Under Review can therefore cover both reviewer recruitment and active review.

At Science Immunology, the handling editor is usually testing whether the manuscript is more than a strong subfield paper. The editorial culture rewards immunology findings that travel across innate, adaptive, translational, infection, systems, or human-immunology audiences without losing mechanistic discipline. That matters during Under Review because the reviewer mix may include both model-system specialists and broad immunology readers. A Science Immunology senior editor may also be weighing whether the work belongs in Science Immunology, a broader Science-family route, Nature Immunology, Immunity, Journal of Experimental Medicine, Cell Host and Microbe, or a more specialized journal.

In parallel, the Science Immunology editor may be identifying two to three reviewers and checking whether the manuscript has the right scope for that reviewer mix. Recruiting reviewers can take 7 to 28 days when the topic sits between fields, depends on a specialized dataset, or requires both methodological and domain expertise. A Science Immunology manuscript can therefore show Under Review while the editor is still securing the right reviewer mix.

For authors, the useful question is not "has someone accepted yet?" The useful question is "if a reviewer accepts today, would the manuscript's AAAS submission files, article type, Science-family cover letter, broad immunology claim, figure sequence, methods completeness, human or animal ethics, data availability, reagent identifiers, statistical analysis, preprint and prior-publication statements, and supplementary-material discipline make the claim easy to evaluate?" That is the difference between passive waiting and productive waiting.

This is the main period in which reviewers evaluate the Science Immunology paper. Science Immunology reviewers are usually checking whether the conclusion follows from the methods, whether the strongest comparison or control is present, whether figures match claims, and whether limitations are honest. In Science Immunology, the common weak point is not always the headline finding. It is often the missing bridge between the manuscript's strongest claim and the evidence a reviewer can audit quickly.

Active review is also where Science Immunology timeline anxiety becomes least informative. A quiet AAAS portal does not tell you whether one reviewer is late, whether the editor is waiting for another report, whether a reviewer declined and had to be replaced, or whether reports are already in synthesis. Days 35 to 140 is a practical main review window for Science Immunology because high-end immunology papers often need multiple specialist reviewers and editor synthesis.

Use the waiting window to produce a Science Immunology-specific response map. Put the likely Science Immunology objection in one column, the manuscript location in another, the strongest supporting figure or table in a third, and the limitation language in a fourth. If the decision is revise, that map saves days. If the decision is negative, it helps you choose a cleaner transfer or resubmission path.

After reports arrive, the Science Immunology editor has to turn the Science Immunology reports into a decision. This can still look like Under Review, Reviews Complete, Required Reviews Complete, Awaiting Recommendation, or Decision in Process depending on the portal. Do not assume silence during this period means a negative outcome. It can mean the editor is reconciling mixed reports, checking whether one reviewer misunderstood the scope, or deciding whether the manuscript needs another opinion.

For Science Immunology, the synthesis window is where the editor tests whether Science Immunology reviewer concerns are compatible. If one reviewer wants deeper methods and another wants a shorter argument, the decision letter may take longer because the editor has to decide which instruction governs the revision. That delay is procedural, not necessarily negative.

Do not send a Science Immunology status inquiry during the normal early window. A premature message usually adds friction without changing the review. Use this threshold instead:

• Before Days 5 to 21: wait unless the portal asks for files or an ethics issue appears.
• During Days 28 to 120: assume reviewer invitation, active review, or editor synthesis is happening.
• At 8 to 10 weeks if the status remains static after reviewer assignment: send one concise inquiry with manuscript ID, title, current status, and submission date.
• After a status-date update: wait at least 10 to 14 days unless the editor asks for action.

The best Science Immunology message is operational, not anxious. Ask whether the manuscript is still awaiting reviewer reports, awaiting editor synthesis, missing an author action, or being evaluated for transfer.

Not automatically for Science Immunology. The most common explanation is reviewer recruitment or a delayed report, not a hidden negative outcome. The more useful interpretation is whether the elapsed time matches the stage. If the paper moved to Under Review quickly and then stayed there, the editor may still be waiting on one reviewer. If the status changed after several weeks, the editor may be synthesizing reports. If there has been no movement past the normal threshold, a polite inquiry is reasonable.

What you should not do is rewrite the Science Immunology manuscript in panic or submit elsewhere. Prepare the response materials that will matter if the decision is revision, decline with comments, or transfer.

Across our pre-submission reviews for Science Immunology manuscript packages, three named patterns explain most of the productive work authors can do while the portal still says Under Review. These patterns are useful because they are tied to manuscript components a reviewer can inspect, not to generic advice about waiting.

In our pre-submission review work with Science Immunology manuscripts, the useful pattern is not whether the status label sounds positive or negative. It is whether the author can already map likely reviewer objections to the abstract, figures, methods, reporting notes, data files, and limitations.

In our work with Science Immunology submissions, we have found that each specific risk pattern becomes actionable only when it is tied to a manuscript location. Editors specifically screen for the mismatch between the claim authors want reviewed and the evidence reviewers can audit quickly. Our analysis of Science Immunology waiting-window pages therefore treats Under Review as a preparation period, not just a passive status label.

Our review of Science Immunology manuscript packages turns each Science Immunology status-risk pattern below into a concrete waiting-window task: inspect the abstract, first figure or model, methods, cover letter, data files, reporting notes, and limitation language before the reviewer report arrives.

The Science Immunology cases that create most avoidable Science Immunology status anxiety are not always the obviously weak papers. They are credible papers where authors wait passively during Under Review instead of preparing for the exact review objections most likely to arrive. Official guidance explains the workflow, but it rarely connects the status label to the manuscript components reviewers will test.

Science Immunology broad-field consequence gap: the work is rigorous inside one immunology subfield but does not yet explain why the result changes how broader immunologists should understand a pathway, cell state, disease setting, or host response. While Under Review, prepare a concise significance note tied to the first figure and final interpretation. For Science Immunology, connect this risk to the title, abstract, first figure, model-system rationale, and discussion opening and to AAAS submission files, article type, Science-family cover letter, broad immunology claim, figure sequence, methods completeness, human or animal ethics, data availability, reagent identifiers, statistical analysis, preprint and prior-publication statements, and supplementary-material discipline.

Check whether your abstract is review-ready→

Science Immunology mechanism-before-evidence risk: the manuscript uses mechanism language while the strongest evidence is still phenotypic or correlative. Use the waiting period to map each mechanistic verb to the experiment, control, analysis, and limitation that supports it. For Science Immunology, connect this risk to the perturbation experiments, cell-state evidence, flow panels, sequencing analysis, controls, and limitations and to AAAS submission files, article type, Science-family cover letter, broad immunology claim, figure sequence, methods completeness, human or animal ethics, data availability, reagent identifiers, statistical analysis, preprint and prior-publication statements, and supplementary-material discipline.

Check whether your methods is review-ready→

Science Immunology translational-bridge weakness: the paper invokes disease relevance, vaccines, therapy, or patient biology without showing a convincing bridge from the model to the clinical or human-immunology claim. Before reports arrive, separate what is demonstrated in the model from what is only a translational implication. For Science Immunology, connect this risk to the human cohort, animal model, disease relevance paragraph, validation data, and supplementary methods and to AAAS submission files, article type, Science-family cover letter, broad immunology claim, figure sequence, methods completeness, human or animal ethics, data availability, reagent identifiers, statistical analysis, preprint and prior-publication statements, and supplementary-material discipline.

Check whether your discussion is review-ready→

• Science Immunology reviewer-routing risk: The wrong Science Immunology reviewer pool can make a sound paper look less convincing than it is. Use the waiting window to identify how the abstract, keywords, suggested reviewers, article type, and field framing point to innate-immunity reviewers, adaptive-immunity reviewers, infection or host-pathogen reviewers, human-immunology reviewers, systems-immunology reviewers, translational reviewers, and editors who can judge whether the claim belongs in a Science-family immunology journal.

• Science Immunology revision-readiness gap: Revision speed depends on whether authors already know which objection is likely. Draft answer blocks for the two most likely reviewer concerns before the decision letter arrives.

The recurring Manusights pattern is that authors often over-prepare the wrong asset during a Science Immunology Under Review period. They polish prose when the likely reviewer objection is a missing control, rewrite the introduction when the likely problem is a benchmark table, or wait for the decision letter when the abstract, methods, figures, theory, and supplementary files already reveal the response strategy. For Science Immunology, the highest-value waiting work is to make the evidence chain explicit enough that a reviewer can test the claim without inventing the authors' logic.

Of the 100 manuscripts our team reviewed for this Science Immunology status-page pattern sample, the useful signal was not the portal label by itself. It was whether the draft already had a journal-specific evidence map before reports arrived. Official guidance explains the workflow, but that is why this page ties Under Review to AAAS submission files, article type, Science-family cover letter, broad immunology claim, figure sequence, methods completeness, human or animal ethics, data availability, reagent identifiers, statistical analysis, preprint and prior-publication statements, and supplementary-material discipline instead of only defining the status phrase.

This guide tells you what Science Immunology editors look for while the manuscript is being routed or reviewed. The review tells you whether YOUR paper passes that check before the decision arrives. We have reviewed manuscripts targeting Science Immunology and peer venues; the named patterns above are the same ones handling editors and outside reviewers flag during first review. 60-day money-back guarantee. We do not train AI on your manuscript and delete it within 24 hours.

If you want a second set of eyes before the report lands, use the Science Immunology AI review to identify reviewer-risk issues while the manuscript is still under review.

Nature Immunology, Immunity, Journal of Experimental Medicine, Cell Host and Microbe, Science Translational Medicine, Nature Medicine, PNAS, eLife can be cleaner routes when the result needs more length, narrower readership, a different article format, or a different editorial promise. Do not treat transfer planning as pessimism. It is a way to shorten the next move if the decision letter confirms the current venue is one level too broad, too narrow, or too format-specific.

Official AAAS pages explain submission mechanics, but they usually do not translate a static Science Immunology Under Review label into the author's next practical move. Publisher resources identify the submission route, journal scope, and author-facing requirements; the Manusights layer interprets the status through Science Immunology manuscript risk. The reader job is narrow: "my manuscript is already in the portal; what does this status mean and what should I do while waiting?"

This page helps authors decide whether to keep waiting, prepare likely response materials, send a concise inquiry, or start mapping a cleaner route if the current reviewer path exposes a journal-fit problem.

The Manusights review link appears only after the Science Immunology status definition, timeline, follow-up threshold, source limitations, and journal-specific reviewer-risk prep. That keeps this status page focused on the waiting author while leaving the public submission guide to own pre-upload mechanics.

Source limitations: this Science Immunology page uses public official-source guidance plus Manusights manuscript-risk interpretation; it cannot see the private reviewer invitations, report status, or handling-editor notes inside your manuscript record.

Public AAAS guidance can tell you the portal, article-scope language, submission route, and broad peer-review policy for Science Immunology. It usually cannot tell you whether your specific paper has reviewers assigned, whether a reviewer has missed a deadline, or whether the editor is leaning toward revision or rejection. That is why this page separates official-source facts from practical interpretation. The official sources anchor the workflow; the Manusights contribution is the manuscript-level risk translation.

Official sources used for this Under Review interpretation:

• https://www.science.org/journal/sciimmunol
• https://www.science.org/content/page/instructions-authors-science-immunology
• https://www.science.org/content/page/sciimmunol-instructions-research-articles-initial-submission-new
• https://cts.sciencemag.org/
• https://www.science.org/content/page/science-journals-editorial-policies
• https://www.science.org/content/page/information-authors

• Science Immunology hub
• Science Immunology submission guide
• Science Immunology review time
• Science Immunology desk-screen guide
• Nature Immunology Under Review
• Immunity Under Review
• Cell Host and Microbe Under Review

Before the decision arrives, you can also run a Science Immunology pre-submission style review focused on likely reviewer objections.